Employees – University of Copenhagen

Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. / Gloriam, David E.; Wellendorph, Petrine; Johansen, Lars Dan; Thomsen, Alex Rojas Bie; Phonekeo, Karina; Pedersen, Daniel Sejer; Bräuner-Osborne, Hans.

In: Chemistry & Biology, Vol. 18, No. 11, 23.11.2011, p. 1489-1498.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Gloriam, DE, Wellendorph, P, Johansen, LD, Thomsen, ARB, Phonekeo, K, Pedersen, DS & Bräuner-Osborne, H 2011, 'Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor' Chemistry & Biology, vol. 18, no. 11, pp. 1489-1498. https://doi.org/10.1016/j.chembiol.2011.09.012

APA

Gloriam, D. E., Wellendorph, P., Johansen, L. D., Thomsen, A. R. B., Phonekeo, K., Pedersen, D. S., & Bräuner-Osborne, H. (2011). Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. Chemistry & Biology, 18(11), 1489-1498. https://doi.org/10.1016/j.chembiol.2011.09.012

Vancouver

Gloriam DE, Wellendorph P, Johansen LD, Thomsen ARB, Phonekeo K, Pedersen DS et al. Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. Chemistry & Biology. 2011 Nov 23;18(11):1489-1498. https://doi.org/10.1016/j.chembiol.2011.09.012

Author

Gloriam, David E. ; Wellendorph, Petrine ; Johansen, Lars Dan ; Thomsen, Alex Rojas Bie ; Phonekeo, Karina ; Pedersen, Daniel Sejer ; Bräuner-Osborne, Hans. / Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor. In: Chemistry & Biology. 2011 ; Vol. 18, No. 11. pp. 1489-1498.

Bibtex

@article{77646c6e1ea44eb0bd785ffb80e20ea5,
title = "Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor",
abstract = "GPRC6A is a Family C G protein-coupled receptor recently discovered and deorphanized by our group. This study integrates chemogenomic ligand inference, homology modeling, compound synthesis, and pharmacological mechanism-of-action studies to disclose two noticeable results of methodological and pharmacological character: (1) chemogenomic lead identification through the first, to our knowledge, ligand inference between two different GPCR families, Families A and C; and (2) the discovery of the most selective GPRC6A allosteric antagonists discovered to date. The unprecedented inference of pharmacological activity across GPCR families provides proof-of-concept for in silico approaches against Family C targets based on Family A templates, greatly expanding the prospects of successful drug design and discovery. The antagonists were tested against a panel of seven Family A and C G protein-coupled receptors containing the chemogenomic binding sequence motif where some of the identified GPRC6A antagonists showed some activity. However, three compounds with at least ~3-fold selectivity for GPRC6A were discovered, which present a significant step forward compared with the previously published GPRC6A antagonists, calindol and NPS 2143, which both display ~30-fold selectivity for the calcium-sensing receptor compared to GPRC6A. The antagonists constitute novel research tools toward investigating the signaling mechanism of the GPRC6A receptor at the cellular level and serve as initial ligands for further optimization of potency and selectivity enabling future ex vivo/in vivo pharmacological studies.",
keywords = "The Faculty of Pharmaceutical Sciences",
author = "Gloriam, {David E.} and Petrine Wellendorph and Johansen, {Lars Dan} and Thomsen, {Alex Rojas Bie} and Karina Phonekeo and Pedersen, {Daniel Sejer} and Hans Br{\"a}uner-Osborne",
note = "Copyright {\circledC} 2011 Elsevier Ltd. All rights reserved.",
year = "2011",
month = "11",
day = "23",
doi = "10.1016/j.chembiol.2011.09.012",
language = "English",
volume = "18",
pages = "1489--1498",
journal = "Chemistry and Biology",
issn = "2451-9448",
publisher = "Elsevier",
number = "11",

}

RIS

TY - JOUR

T1 - Chemogenomic discovery of allosteric antagonists at the GPRC6A receptor

AU - Gloriam, David E.

AU - Wellendorph, Petrine

AU - Johansen, Lars Dan

AU - Thomsen, Alex Rojas Bie

AU - Phonekeo, Karina

AU - Pedersen, Daniel Sejer

AU - Bräuner-Osborne, Hans

N1 - Copyright © 2011 Elsevier Ltd. All rights reserved.

PY - 2011/11/23

Y1 - 2011/11/23

N2 - GPRC6A is a Family C G protein-coupled receptor recently discovered and deorphanized by our group. This study integrates chemogenomic ligand inference, homology modeling, compound synthesis, and pharmacological mechanism-of-action studies to disclose two noticeable results of methodological and pharmacological character: (1) chemogenomic lead identification through the first, to our knowledge, ligand inference between two different GPCR families, Families A and C; and (2) the discovery of the most selective GPRC6A allosteric antagonists discovered to date. The unprecedented inference of pharmacological activity across GPCR families provides proof-of-concept for in silico approaches against Family C targets based on Family A templates, greatly expanding the prospects of successful drug design and discovery. The antagonists were tested against a panel of seven Family A and C G protein-coupled receptors containing the chemogenomic binding sequence motif where some of the identified GPRC6A antagonists showed some activity. However, three compounds with at least ~3-fold selectivity for GPRC6A were discovered, which present a significant step forward compared with the previously published GPRC6A antagonists, calindol and NPS 2143, which both display ~30-fold selectivity for the calcium-sensing receptor compared to GPRC6A. The antagonists constitute novel research tools toward investigating the signaling mechanism of the GPRC6A receptor at the cellular level and serve as initial ligands for further optimization of potency and selectivity enabling future ex vivo/in vivo pharmacological studies.

AB - GPRC6A is a Family C G protein-coupled receptor recently discovered and deorphanized by our group. This study integrates chemogenomic ligand inference, homology modeling, compound synthesis, and pharmacological mechanism-of-action studies to disclose two noticeable results of methodological and pharmacological character: (1) chemogenomic lead identification through the first, to our knowledge, ligand inference between two different GPCR families, Families A and C; and (2) the discovery of the most selective GPRC6A allosteric antagonists discovered to date. The unprecedented inference of pharmacological activity across GPCR families provides proof-of-concept for in silico approaches against Family C targets based on Family A templates, greatly expanding the prospects of successful drug design and discovery. The antagonists were tested against a panel of seven Family A and C G protein-coupled receptors containing the chemogenomic binding sequence motif where some of the identified GPRC6A antagonists showed some activity. However, three compounds with at least ~3-fold selectivity for GPRC6A were discovered, which present a significant step forward compared with the previously published GPRC6A antagonists, calindol and NPS 2143, which both display ~30-fold selectivity for the calcium-sensing receptor compared to GPRC6A. The antagonists constitute novel research tools toward investigating the signaling mechanism of the GPRC6A receptor at the cellular level and serve as initial ligands for further optimization of potency and selectivity enabling future ex vivo/in vivo pharmacological studies.

KW - The Faculty of Pharmaceutical Sciences

U2 - 10.1016/j.chembiol.2011.09.012

DO - 10.1016/j.chembiol.2011.09.012

M3 - Journal article

VL - 18

SP - 1489

EP - 1498

JO - Chemistry and Biology

JF - Chemistry and Biology

SN - 2451-9448

IS - 11

ER -

ID: 35437152